NadineJacksonMcClearyMD

Hematology • Boston, MA

Myeloproliferative Disorder Hematology-Oncology

Instructor in Medicine, Dana-Farber Cancer Institute

Join to view full profile

Dr. McCleary is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. McCleary's full profile

Already have an account?

Office
450 Brookline Ave
Dana-Farber Cancer Institu
Boston, MA 02115

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2006 - 2009
Johns Hopkins UniversityResidency, Internal Medicine, 2003 - 2006
Johns Hopkins University School of MedicineClass of 2002

Certifications & Licensure

FL State Medical License 2022 - Present
CT State Medical License 2022 - 2025
MA State Medical License 2007 - 2025
American Board of Internal Medicine Medical Oncology

Clinical Trials

Routine Evaluation of the Social Determinants of Health in Oncology: User-centered Resource Coordination and Engagement Start of enrollment: 2021 May 17
Completed
Not Applicable
Roles: Principal Investigator, Contact
SURGE: Supporting UnderRepresented Minorities in Genomics-based Cancer Trial Enrollment (Intervention) Start of enrollment: 2023 Apr 03
Recruiting
Not Applicable
Roles: Contact, Principal Investigator, Sponsor-Investigator
Resilience and Equity in Aging, Cancer, and Health (REACH) Start of enrollment: 2022 Jan 18
Recruiting
Not Applicable
Roles: Principal Investigator, Contact

Publications & Presentations

PubMed

143 citations
Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis
Rawad Elias, Anita Giobbie-Hurder, Nadine Jackson McCleary, Patrick A. Ott, F. Stephen Hodi
Journal for Immunotherapy of Cancer. 2018-04-04
280 citations
Phase II and Pharmacodynamic Study of Autophagy Inhibition Using Hydroxychloroquine in Patients With Metastatic Pancreatic Adenocarcinoma
Brian M. Wolpin, Douglas A. Rubinson, Xiaoxu Wang, Jennifer A. Chan, James M. Cleary
The Oncologist. 2014-06-01
59 citations
Combined PD-1, BRAF and MEK inhibition in BRAFcolorectal cancer: a phase 2 trial.
Jun Tian, Jonathan H Chen, Sherry X Chao, Karin Pelka, Marios Giannakis
Nature Medicine. 2023-02-01

Press Mentions

SURGE: Supporting UnderRepresented Minorities in Genomics-Based Cancer Trial Enrollment (Intervention)May 16th, 2022
UA College of Medicine Selected for an Internship ProgramJuly 20th, 2021
Mom Diagnosed with Stage 4 Cancer After Pregnancy Encourages Women to Trust Their InstinctsFebruary 21st, 2020